HFA Premium Access

Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis

Congress Presentation

About the speaker

Mrs Emmanuelle Lointier

Rangueil Hospital of Toulouse, Toulouse (France)
0 follower

7 more presentations in this session

Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

Speaker: Doctor M. Maurer (New York, US)

Thumbnail

T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.

Speaker: Ms M. Diez (Buenos Aires, AR)

Thumbnail

Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis

Speaker: Doctor G. Sinigiani (Padova, IT)

Thumbnail

Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis

Speaker: Doctor A. Jakstaite (Hannover, DE)

Thumbnail

Utility of KAsH score in predicting in-hospital mortality in takotsubo cardiomyopathy

Speaker: Doctor I. Martins Moreira (Vila Real, PT)

Thumbnail

Access the full session

Myocardial disease - clinical 5

Speakers: Mrs E. Lointier, Doctor M. Maurer, Ms M. Diez, Doctor G. Sinigiani, Doctor A. Jakstaite...
Thumbnail

About the event

Image

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations